A 38-year-old female from rural Maharashtra presents with a 3-month history of progressive numbness and tingling in her feet, followed by weakness in her lower limbs. On examination, she has diminished vibration and proprioception sense in both lower limbs, and a positive Romberg sign. Her diet consists mainly of polished rice and legumes with minimal animal products. Serum methylmalonic acid and homocysteine levels are elevated. What is the most appropriate next step in management?

Explanation

## Clinical Diagnosis This patient presents with **subacute combined degeneration (SCD)** secondary to **vitamin B₁₂ deficiency**. The clinical triad of sensory ataxia (positive Romberg), peripheral neuropathy (numbness/tingling), and elevated methylmalonic acid + homocysteine confirms B₁₂ deficiency with neurological manifestation. **Key Point:** Elevated methylmalonic acid and homocysteine are pathognomonic for B₁₂ deficiency. These metabolites accumulate because B₁₂ (as methylcobalamin) is essential for methylmalonyl-CoA mutase and methionine synthase. ## Why Intramuscular B₁₂ is Correct ### Rationale 1. **Neurological involvement mandates parenteral therapy**: Once demyelination of the posterior and lateral columns has begun, oral supplementation is inadequate. Parenteral B₁₂ achieves higher tissue concentrations and crosses the blood–brain barrier more effectively. 2. **Dietary deficiency context**: Rural diet with minimal animal products (meat, eggs, dairy) is the likely cause; malabsorption is less likely given no GI symptoms. 3. **Dosing regimen**: 1000 µg IM weekly for 6 weeks (loading phase) followed by monthly maintenance is the standard protocol for neurological B₁₂ deficiency [cite:Harrison 21e Ch 405]. 4. **Urgency**: Neurological damage becomes irreversible if B₁₂ repletion is delayed beyond 6–12 months; early aggressive replacement prevents permanent disability. **Clinical Pearl:** Once neurological signs appear, the window for full recovery is limited. Parenteral B₁₂ within weeks of symptom onset offers the best chance of neurological reversal. **High-Yield:** Methylmalonic acid elevation = B₁₂ deficiency (methylmalonyl-CoA mutase block). Homocysteine elevation alone = B₁₂ or folate deficiency (methionine synthase block). ## Mechanism of B₁₂ in Neurological Disease ```mermaid flowchart TD A[B12 Deficiency]:::outcome --> B[Impaired Methylmalonyl-CoA Mutase<br/>& Methionine Synthase]:::outcome B --> C[Accumulation of methylmalonic acid<br/>& homocysteine]:::outcome C --> D[Myelin destabilization<br/>& neuronal apoptosis]:::outcome D --> E{Neurological Symptoms<br/>Present?}:::decision E -->|Yes| F[Parenteral B12 IM<br/>1000 µg weekly × 6 weeks]:::action E -->|No| G[Oral B12 supplementation]:::action F --> H[Neurological recovery<br/>if <6 months duration]:::outcome G --> I[Monitor serum B12<br/>& metabolites]:::action ``` ## Why Other Options Are Suboptimal | Option | Why It Fails | |--------|-------------| | **Oral folic acid alone** | Folate does not correct B₁₂ deficiency; worse, it may mask megaloblastic anemia while neurological damage progresses ("masking" trap). Homocysteine and methylmalonic acid remain elevated. | | **Upper GI endoscopy** | Useful to diagnose pernicious anemia (intrinsic factor antibodies, atrophic gastritis), but this patient has dietary deficiency, not malabsorption. Endoscopy delays definitive treatment and does not address acute neurological emergency. | | **Thiamine supplementation** | Thiamine (B₁) deficiency causes Wernicke–Korsakoff syndrome (ophthalmoplegia, ataxia, confusion), not subacute combined degeneration. No elevated methylmalonic acid in thiamine deficiency. | **Warning:** Do not give oral B₁₂ in established neurological B₁₂ deficiency—bioavailability is poor (~1–2%) and neurological progression may continue while clinicians await oral absorption.